On September 3, 2020 MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, reported that the Company’s management will participate in the following investor conferences in September (Press release, MacroGenics, SEP 3, 2020, View Source [SID1234564388]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 15th Annual BioPharma Virtual Conference. MacroGenics’ management will participate in one-on-one meetings and present in the "Novel Antibodies and Protein Therapeutics in Oncology" panel on September 10, 2020 at 10:45 AM ET.
HC Wainwright & Co. 22nd Annual Global Investment Conference. MacroGenics’ management will participate in one-on-one meetings and provide a corporate overview on September 14, 2020 at 10:00 AM ET.
Cantor Virtual Global Healthcare Conference. MacroGenics’ management will participate in one-on-one meetings and provide a corporate overview on September 16, 2020 at 8:00 AM ET.
Morgan Stanley 18th Annual Global Healthcare Conference. MacroGenics’ management will participate in one-on-one meetings and a fireside chat on September 17, 2020 at 2:45 PM ET.
Webcasts of each presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at View Source The Company will maintain archived replays of these webcasts on its website for 30 days after each conference.